The nearly doubled median OS is a strong efficacy signal for gotistobart in a difficult-to-treat population. Traders should watch for updates from the pivotal stage 2 of PRESERVE-003 and any regulatory interactions. Positive data could significantly de-risk the asset and support BioNTech's oncology pipeline beyond COVID.
Price Chart
Executive Summary
BioNTech and OncoC4 announced positive median overall survival (OS) data from stage 1 of the PRESERVE-003 Phase 3 trial for gotistobart in squamous NSCLC patients who progressed on prior immunotherapy and chemotherapy. Gotistobart nearly doubled median OS to 18.5 months vs 10.0 months for docetaxel (HR: 0.56, p=0.0295), a statistically significant and clinically meaningful result. The data were presented at WCLC 2026 and support the ongoing pivotal stage 2 of the trial.
Key Facts
- Gotistobart showed median OS of 18.5 months vs 10.0 months for docetaxel (HR: 0.56, p=0.0295)
- Data from non-pivotal stage 1 of PRESERVE-003 Phase 3 trial in squamous NSCLC patients after prior immunotherapy and chemotherapy
- Pivotal stage 2 of PRESERVE-003 is ongoing at >160 sites globally
- Gotistobart received Fast Track Designation from FDA (2022) and Orphan Drug Designation for squamous NSCLC (2025)
- Safety profile manageable: Grade ≥3 treatment-related AEs in 44.4% (gotistobart) vs 48.8% (docetaxel)
Financial Impact
Potential multi-billion dollar peak sales opportunity if approved in second-line squamous NSCLC, a large market with limited options
Risk Factors
- Stage 1 data is non-pivotal; pivotal stage 2 results are needed for registration
- Competition from other CTLA-4 and novel immunotherapies in NSCLC
- Regulatory approval not guaranteed; safety and manufacturing reviews remain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3360734 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.61 (+5.36%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.61 (−12.88%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.61 (+4.10%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.61 (−5.75%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.61 (+4.04%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.61 (+12.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access